| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BCP.2015.12.005 |
| P698 | PubMed publication ID | 26707800 |
| P2093 | author name string | Carlo Petosa | |
| Charles E McKenna | |||
| Elena Ferri | |||
| P2860 | cites work | Crystal structure of the nucleosome core particle at 2.8 A resolution | Q22122355 |
| Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 1-18 | |
| P577 | publication date | 2015-12-18 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Bromodomains: Structure, function and pharmacology of inhibition | |
| P478 | volume | 106 |
| Q39207675 | A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers |
| Q28552504 | A Novel Phenanthridionone Based Scaffold As a Potential Inhibitor of the BRD2 Bromodomain: Crystal Structure of the Complex |
| Q52598516 | Activity of bromodomain protein inhibitors/binders against asexual-stage Plasmodium falciparum parasites. |
| Q58693141 | Adenovirus E1A Activation Domain Regulates H3 Acetylation Affecting Varied Steps in Transcription at Different Viral Promoters |
| Q61810267 | BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT |
| Q90333805 | BET Proteins Are Required for Transcriptional Activation of the Senescent Islet Cell Secretome in Type 1 Diabetes |
| Q52589764 | BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo. |
| Q33725257 | Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains |
| Q57063034 | Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy |
| Q46924536 | Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma |
| Q38906390 | Bromodomain 4: a cellular Swiss army knife |
| Q42694831 | Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model |
| Q38771703 | Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development |
| Q91623240 | Bromodomains: a new target class for drug development |
| Q39423291 | Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation |
| Q33751386 | Chemical probes targeting epigenetic proteins: Applications beyond oncology |
| Q95925843 | Chromatin remodelers in oligodendroglia |
| Q47913271 | Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains. |
| Q38291894 | Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders |
| Q58977704 | Discovery and lead identification of quinazoline-based BRD4 inhibitors |
| Q57822336 | Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry |
| Q91011911 | E2F1 acetylation directs p300/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair |
| Q28071912 | Epigenetic modulators as therapeutic targets in prostate cancer |
| Q63246733 | Flavonoids as Putative Epi-Modulators: Insight into Their Binding Mode with BRD4 Bromodomains Using Molecular Docking and Dynamics |
| Q40577464 | Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer |
| Q89605002 | Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses |
| Q55248424 | Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. |
| Q50091965 | Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1. |
| Q92025158 | Inhibition of BRD4 prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis |
| Q57068289 | Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression |
| Q64261100 | JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo |
| Q64229588 | Making Sense of the Epigenome Using Data Integration Approaches |
| Q42362250 | Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins. |
| Q37688355 | Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis |
| Q52714957 | Plk1 inhibition enhances the efficacy of BET epigenetic reader blockade in castration-resistant prostate cancer. |
| Q46253902 | Polycomb and Trithorax Group Genes in Drosophila |
| Q54978951 | Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity. |
| Q38935390 | Protein-protein interaction inhibitors: advances in anticancer drug design. |
| Q93119673 | Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists |
| Q41637362 | Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked |
| Q61799027 | Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment |
| Q30354737 | Selective BET bromodomain inhibition as an antifungal therapeutic strategy |
| Q38748150 | Selective targeting of epigenetic reader domains |
| Q90371179 | Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases |
| Q28829832 | Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor |
| Q47660875 | Super enhancers - new analyses and perspectives on the low hanging fruit |
| Q93352829 | Tannic acid, a novel histone acetyltransferase inhibitor, prevents non-alcoholic fatty liver disease both in vivo and in vitro model |
| Q90442118 | Targeting Brd4 for cancer therapy: inhibitors and degraders |
| Q47385983 | Targeting bromodomain and extraterminal proteins in breast cancer |
| Q51803048 | Targeting vasa vasorum dysfunction to prevent atherosclerosis. |
| Q47288294 | Temporal regulation of chromatin during myoblast differentiation. |
| Q89207844 | The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells |
| Q39208675 | The MYCN Protein in Health and Disease |
| Q49483734 | The identification of new ATAD2 bromodomain inhibitors: the application of combined ligand and structure-based virtual screening. |
| Q103805423 | USP24 stabilizes bromodomain containing proteins to promote lung cancer malignancy |
| Q55087013 | Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease. |
Search more.